Akèy › Kansè nan tete › North Carolina › Charlotte
Etid klinik pou Kansè nan tete nan Charlotte, NC
22 etid pou Kansè nan tete ap chèche patisipan nan sit nan ak bò kote Charlotte (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
Ap rekriteFaz 2
- Levine Cancer, Charlotte
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
Ap rekriteFaz 1
- Carolina BioOncology Institute, LLC - Cancer Therapy and Research Center, Huntersville · 13 mi lwen
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
Ap rekriteFaz 3
- Novant Health Cancer Institute ( Site 0019), Charlotte
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Ap rekriteFaz 3
- Levine Cancer Institute ( Site 0014), Charlotte
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
Ap rekriteFaz 3
- Levine Cancer Institute, Charlotte
- Levine Cancer Institute, Charlotte
- Levine Cancer Institute, Charlotte
- ak 7 plis
Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy
Ap rekrite
- Carolinas Medical Center/Levine Cancer Institute, Charlotte
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
Ap rekrite
- Atrium Levine Cancer Institute, Charlotte
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
Ap rekriteFaz 3
- Clinical Trial Site, Charlotte
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
Ap rekriteFaz 3
- Atrium Health, Charlotte
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
Ap rekriteFaz 3
- Oncology Specialists of Charlotte Pa, Charlotte
- Carolina Oncology Specialists, Charlotte
Utility of a Mobile Application for Young Women With Breast Cancer
Ap rekrite
- Atrium Health Levine Cancer, Charlotte
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
Ap rekriteFaz 1/2
- Research Site, Charlotte
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
Ap rekriteFaz 1/2
- Levine Cancer Institute, Charlotte
- Novant Health Cancer Institute, Charlotte
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Ap rekriteFaz 3
- Novant Health Cancer Institute, Charlotte
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Ap rekriteFaz 3
- Carolinas Medical Center/Levine Cancer Institute, Charlotte
- Novant Health Presbyterian Medical Center, Charlotte
- Atrium Health Pineville/LCI-Pineville, Charlotte
- ak 12 plis
E-Mindfulness Approaches for Living After Breast Cancer
Ap rekriteFaz 3
- Carolinas Medical Center/Levine Cancer Institute, Charlotte
- Atrium Health Pineville/LCI-Pineville, Charlotte
- Levine Cancer Institute-SouthPark, Charlotte
- ak 7 plis
A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
Ap rekriteFaz 2
- GSK Investigational Site, Charlotte
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Ap rekriteFaz 1/2
- Carolina BioOncology Institute, Huntersville · 13 mi lwen
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Ap rekriteFaz 3
- Carolinas Medical Center/Levine Cancer Institute, Charlotte
- Novant Health Presbyterian Medical Center, Charlotte
- Atrium Health Pineville/LCI-Pineville, Charlotte
- ak 10 plis
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
Ap rekriteFaz 1/2
- Levine Cancer Institute (LCI)- Atrium Health, Charlotte
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Ap rekriteEtid obsèvasyon
- Carolinas Medical Center/Levine Cancer Institute, Charlotte
- Atrium Health Pineville/LCI-Pineville, Charlotte
- Levine Cancer Institute-SouthPark, Charlotte
- ak 8 plis
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
Ap rekriteEtid obsèvasyon
- Atrium Health Levine Cancer Institute, Charlotte
- Novant Health Cancer Institute - Elizabeth, Charlotte
Etid Kansè nan tete nan lòt vil
- New York City, NY136 etid
- Houston, TX126 etid
- Boston, MA112 etid
- Nashville, TN81 etid
- Los Angeles, CA73 etid
- Edison, NJ68 etid
- St. Louis, MO64 etid
- Queens, NY64 etid
- Durham, NC64 etid
- Chicago, IL59 etid
- Philadelphia, PA56 etid
- Dallas, TX55 etid
Lòt etid nan Charlotte
- Kansè (tout kalite)27 etid
- Myelom Miltip21 etid
- Kansè Poumon ki pa ti selil19 etid
- Leksemi mieloïd egi16 etid
- Obèsite16 etid
- Sipwa15 etid
- Kansè kolorektal13 etid
- Kansè ovè12 etid
- Ensifizyans kadyak11 etid
- Kansè Metastatik11 etid
- Karsinòm selil skuamèz tèt ak kou10 etid
- BPCO9 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.